Org 30029 (hydrochloride) is a Ca2+ sensitizer with positive inotropic effect. Org 30029 (hydrochloride) can be used for the research of cardiovascular disease.

Hepoxilin A3 methyl ester is the ester form of HxA3. Hepoxilin A3 methyl ester causes a receptor-induced rise in intracellular calcium through the release from intracellular stores in suspended human neutrophils.

S 16317 is an orally active dihydropyridine derivative with low calcium channel affinity (Ki: 0.55 μM). S 16317 inhibits P-gp mediated efflux of ADR. S 16317 overcomes multidrug resistance in tumor.

SL-870495 is a calcium antagonist targeting L-type calcium channels. SL-870495 is promising for research of cardiovascular diseases such as hypertension and angina pectoris.

HM12 is a covalent inhibitor of L-/T-type calcium channels. HM12 can strongly inhibit the Cav1.2 (L-type) and Cav3.2 (T-type) calcium channels, and has selectivity for the N-type channels. HM12 produces an irreversible inhibition that persisted after washout. HM12 can be used to study diseases such as hypertension, pain, epilepsy, etc.

F-0401 is a calcium antagonist with platelet-activating factor receptor (PAFR) antagonistic action. F-0401 can be used for the research of neurological disease, such as stroke.

Onychocin B is a cyclic tetrapeptide isolated from Onychocola sclerotica. Onychocin B is a calcium channel blocker with an IC50 of 7.1 μM for Cav1.2.

D-myo-Inositol-1,2,6-triphosphate (sodium) is one of the members in inositol phosphate family of second messengers that play an important role in transmitting cellular signals. D-myo-Inositol-1,2,6-triphosphate (sodium) can open calcium channels and increase intracellular calcium upon binding to its receptor on the endoplasmic reticulum.

D-myo-Inositol-2,3,5,6-tetraphosphate (2,3,5,6-IP4) tetrasodium is a inositol phosphate. D-myo-Inositol-2,3,5,6-tetraphosphate tetrasodium can be used for the study of calcium channels.

D-myo-Inositol-2,4,5-triphosphate (Ins(2,4,5)P3) (sodium salt) is a second messenger produced in cells by phospholipase C-mediated hydrolysis of phosphatidylinositol-4,5-biphosphate. D-myo-Inositol-2,4,5-triphosphate (sodium salt) can open calcium channels and increase intracellular calcium upon binding to its receptors on the endoplasmic reticulum. D-myo-Inositol-2,4,5-triphosphate (sodium salt) also acts as a partial agonist at rat hepatic IP3 receptors. D-myo-Inositol-2,4,5-triphosphate (sodium salt) can be studied in research on calcium ions signaling pathway.

D-myo-Inositol-1,2,4,5,6-pentaphosphate (Ins(1,2,4,5,6)P5) sodium salt is one of several different inositol oligophosphate isomers involved in signal transduction. In human Jurkat T lymphocytes, Ins(1,2,4,5,6)P5 (sodium salt) is phosphorylated to InsP6 by 1/3 kinase. D-myo-Inositol-1,2,4,5,6-pentaphosphate sodium salt is involved in calcium signaling.

HCA-6 is a calcium-channel and P-glycoprotein blocker. HCA-6 can induce cancer cells apoptosis and increase anticancer activity of Cisplatin. HCA-6 also exhibits antibacterial activity against Bacillus subtilis. HCA-6 can be used for the research of cancer and infection, such as breast cancer.

D-myo-inositol-1,2,3,5-tetraphosphate (Ins(1,2,3,5,6)-P5) tetrasodium is one of the Inositol phosphate isomers and can act as a soluble second messenger to participate in cellular calcium signaling.

D-myo-Inositol-1,2,4,5-tetraphosphate (DL-Ins-(1,2,4,5)P4) tetrasodium is raracemic regioisomer of myo-inositol tetrakisphosphates (IP4s). D-myo-Inositol-1,2,4,5-tetraphosphate tetrasodium is an Ins(1,4,5)P3 receptor agonist with a Ki of 11 nM. D-myo-Inositol-1,2,4,5-tetraphosphate tetrasodium induces Ca2+ mobilization with an EC50 value of 0.22 μM in CHO cells.

Glycerophosphoinositol 4,5-diphosphate (GroPI(4,5)P2) trisodium is a slowly metabolized analog of InsP3. Glycerophosphoinositol 4,5-diphosphate trisodium has an EC50 of 1.228 μM for inducing calcium release, with a degradation time constant of 13 seconds. Glycerophosphoinositol 4,5-diphosphate trisodium can be used to study the effect of InsP3 degradation on calcium signal recovery.

NAADP tetrasodium is a second messenger. NAADP tetrasodium releases Ca2+ from acidic endosomes and lysosomes. NAADP tetrasodium can be used to study cancer (such as oral squamous cell carcinoma, malignant melanoma) and angiogenesis-related diseases.

Wy 27569 is an orally active vascular selective calcium channel blocker that can effectively lower blood pressure. Wy 27569 is a thromboxane synthase inhibitor that can reshape prostaglandin balance, reduce pro thrombotic TXA2, and increase anti thrombotic PGI2. Wy 27569 can be used for research on cardiovascular diseases such as hypertension and angina.

PD 175069 is a potent and selective N-type calcium channel antagonist with an IC50 of 0.32 μM. PD 175069 is efficacious in an audiogenic seizure model using DBA/2 mice. PD 175069 can be used for on neurological conditions such as neuropathic pain and stroke.

Bastadins-5 is a potent stabilizer for the open state of RYR1. Bastadins-5 enhances Ca2+-induced Ca2+ release. Bastadins-5 can be used in research on central nuclear disease and malignant hypothermia.

TTA-A2 is a potent, selective and orally active t-type voltage gated calcium?channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy.

IPPQ is a small molecule that selectively target the interface between the N-type calcium (CaV2.2) channel and CaVβ, specifically binds to CaVβ2a and inhibits CaVβ2's interaction with CaV.2-AID (alpha interacting domain).

O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol. O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2R4496C) mutation (IC50 = 7.62 µM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol in conscious rabbits (ED50s = 32 and 5 µg/kg, respectively).

Niguldipine monohydrochloride is a calcium channel blocker that inhibits P-glycoprotein and can be used in tumor research. Niguldipine monohydrochloride inhibits Cav 3.2, with an IC50 of 0.9 μM.

Hexadecylphosphoserine TFA is a phospholipid molecule that contains a long-chain alkyl (hexadecyl) and a phosphoserine group, giving it a high affinity for the cell membrane. Hexadecylphosphoserine TFA can exert antitumor activity by modulating [Ca++]i and its related signaling pathways, making it useful for research in the field of breast cancer.

Etripamil (MSP-2017) hydrochloride is a short-acting, L-type calcium channel antagonist that can be used in the study of paroxysmal supraventricular tachycardia (PSVT). Etripamil hydrochloride inhibits calcium influx through slow calcium channels, thereby slowing atrioventricular node conduction and prolonging the atrioventricular node refractory period.

dl-Tetrandrine is an orally active and brain-penetrant calcium channel blocker that inhibits voltage-dependent calcium channels. dl-Tetrandrine selectively blocks Ca2+ influx with an IC50 value of approximately 1-10 μM. dl-Tetrandrine exerts anti-inflammatory, immunosuppressive, and anti-arrhythmic activities by inhibiting intracellular calcium overload, and can reverse multidrug resistance in tumor cells. dl-Tetrandrine is promising for research of autoimmune diseases (such as rheumatoid arthritis), cardiovascular diseases, and tumor drug resistance reversal.

CGP 28392 is an activator for calcium channel, and reactivates the oxygen evolution in calcium-deficient photosystem II (PS II) particles.

Cav 3.1 blocker 1 (compound 12) is a T-type calcium channel blocker with an IC50value of 160 nM for Cav3.1. Cav 3.1 blocker 1 weakly inhibits Cav 3.2 (IC50 of 5000 nM), and shows no inhibition on Cav 3.3 and Cav 1.2 (IC50 of >10000 nM).

AK-2-38, a Nifedipine analogue, is a calcium channel antagonist. AK-2-38 also has partial agonist effects on isolated guinea pig left atrium.

Adenophostin A is a potent inositol triphosphate (IP3) receptor agonist, which binds to IP3 receptors with high affinity and effectively stimulates the release of calcium ions (Ca2+).